8 results on '"Shen, Limei"'
Search Results
2. Free PEG Suppresses Anaphylaxis to PEGylated Nanomedicine in Swine.
- Author
-
Shen L, Li Z, Ma A, Cruz-Teran C, Talkington A, Shipley ST, and Lai SK
- Subjects
- Humans, Animals, Swine, Mice, Tissue Distribution, Nanomedicine, Polyethylene Glycols pharmacology, Antibodies metabolism, Liposomes pharmacology, Anaphylaxis chemically induced, Anaphylaxis drug therapy, Anaphylaxis prevention & control
- Abstract
Covalent conjugation of poly(ethylene glycol) (PEG) is frequently employed to enhance the pharmacokinetics and biodistribution of various protein and nanoparticle therapeutics. Unfortunately, some PEGylated drugs can induce elevated levels of antibodies that can bind PEG, i.e., anti-PEG antibodies (APA), in some patients. APA in turn can reduce the efficacy and increase the risks of allergic reactions, including anaphylaxis. There is currently no intervention available in the clinic that specifically mitigates allergic reactions to PEGylated drugs without the use of broad immunosuppression. We previously showed that infusion of high molecular weight free PEG could safely and effectively suppress the induction of APA in mice and restore prolonged circulation of various PEGylated therapeutics. Here, we explored the effectiveness of free PEG as a prophylaxis against anaphylaxis induced by PEG-specific allergic reactions in swine. Injection of PEG-liposomes (PL) resulted in anaphylactoid shock (pseudoanaphylaxis) within 1-3 min in both naïve and PL-sensitized swine. In contrast, repeated injection of free PEG alone did not result in allergic reactions, and injection of free PEG effectively suppressed allergic reactions to PL, including in previously PL-sensitized swine. These results strongly support the further investigation of free PEG for reducing APA and allergic responses to PEGylated therapeutics.
- Published
- 2024
- Full Text
- View/download PDF
3. Optimization of Interface Materials between Bi 2 Te 3 -Based Films and Cu Electrodes Enables a High Performance Thin-Film Thermoelectric Cooler.
- Author
-
Shen L, Chen Y, Niu B, Liu Z, Qin J, and Xie J
- Abstract
Thermoelectric interface materials (TEiMs) are key to optimizing the electrical contact and stability of the interface between thermoelectric material and metal electrode in high-performance thin-film thermoelectric coolers (TECs). Herein, we explored TEiMs applicable to representative Bi-Te films and found that Cr and Ag are effective TEiMs for p-type Bi
0.5 Sb1.5 Te3 and n-type Bi2 Te3 , respectively. By introducing 200 nm Cr and 200 nm Ag as TEiMs for p-type Bi0.5 Sb1.5 Te3 /Cu and n-type Bi2 Te3 /Cu interfaces, Cu diffusion is suppressed, and excellent electrical contact is achieved (1.81 × 10-12 Ω m2 for p-type and 3.32 × 10-12 Ω m2 for n-type) and remains stable after heat treatment (2.37 × 10-12 Ω m2 for p-type and 1.63 × 10-12 Ω m2 for n-type). Furthermore, the cooling flux of TECs with optimized TEiMs increases from 122.74 to 296.56 W/cm2 , while the performance degradation caused by contact resistance decreases from 50.81 to 4.15%. In addition, our results show that diffusion occurs between not only Cu but also Ag and the thermoelectric material, as TEiMs diffuse slightly. The diffusion of Cu and Ag at the interface can optimize the electrical contact of Bi2 Te3 /Cu but strongly degrade the electrical contacts of Bi0.5 Sb1.5 Te3 /Cu. Our work provides an optimal selection of TEiMs for high-performance Bi-Te thin film coolers and provides guidance for further miniaturization of devices.- Published
- 2022
- Full Text
- View/download PDF
4. Nanoformulated Codelivery of Quercetin and Alantolactone Promotes an Antitumor Response through Synergistic Immunogenic Cell Death for Microsatellite-Stable Colorectal Cancer.
- Author
-
Zhang J, Shen L, Li X, Song W, Liu Y, and Huang L
- Subjects
- Animals, Apoptosis drug effects, Colorectal Neoplasms genetics, Drug Delivery Systems, Drug Synergism, Female, Mice, Mice, Inbred BALB C, Micelles, Microsatellite Repeats genetics, Tumor Microenvironment drug effects, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents pharmacology, Colorectal Neoplasms metabolism, Lactones chemistry, Lactones pharmacokinetics, Lactones pharmacology, Nanoparticles chemistry, Nanoparticles metabolism, Quercetin chemistry, Quercetin pharmacokinetics, Quercetin pharmacology, Sesquiterpenes, Eudesmane chemistry, Sesquiterpenes, Eudesmane pharmacokinetics, Sesquiterpenes, Eudesmane pharmacology
- Abstract
Microsatellite-stable colorectal cancer (CRC) is known to be resistant to immunotherapy. The combination of quercetin (Q) and alantolactone (A) was found to induce synergistic immunogenic cell death (ICD) at a molar ratio of 1:4 (Q:A). To achieve ratiometric loading and delivery, the micellar delivery of Q and A (QA-M) was developed with high entrapment efficiency and drug loading at an optimal ratio. QA-M achieved prolonged blood circulation and increased tumor accumulation for both drugs. More importantly, QA-M retained the desired drug ratio (molar ratio of Q to A = 1:4) in tumors at 2 and 4 h after intravenous injection for synergistic immunotherapy. Tumor growth was significantly inhibited in murine orthotopic CRC by the treatment of QA-M compared to PBS and the combination of free drugs ( p < 0.005). The combination of nanotherapy stimulated the host immune response to induce long-term tumor destruction and induced memory tumor surveillance with a 1.3-fold increase in survival median time compared to PBS ( p < 0.0001) and a combination of free drugs ( p < 0.0005). The synergistic therapeutic effect induced by codelivery of Q and A is capable of reactivating antitumor immunity by inducing ICD, causing cell toxicity and modulating the immune-suppressive tumor microenvironment. Such a combination of Q and A with synergistic effects entrapped in a simple and safe nanodelivery system may provide the potential for scale-up manufacturing and clinical applications as immunotherapeutic agents for CRC.
- Published
- 2019
- Full Text
- View/download PDF
5. Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors.
- Author
-
Chen Y, Song W, Shen L, Qiu N, Hu M, Liu Y, Liu Q, and Huang L
- Subjects
- Animals, Liposomes chemistry, Melanoma metabolism, Mice, Tumor Microenvironment physiology, Hydralazine chemistry, Nanoparticles chemistry
- Abstract
Desmoplastic tumors are normally resistant to nanoparticle-based chemotherapy due to dense stroma and limited particle permeability inside the tumor. Herein, we reported that hydralazine (HDZ)-an antihypertension vasodilator-would dramatically promote nanoparticle penetration in advanced desmoplastic tumors. First, a HDZ-liposome system was developed for tumor-selective delivery of HDZ. After three injections of HDZ-liposomes at a dose of 15 mg/kg, the tumor stroma was remarkably reduced, along with ameliorated tumor hypoxia in murine models of desmoplastic melanoma (BPD6). Furthermore, HDZ-liposome treatment altered the immunosuppressive tumor microenvironment, which provided opportunities for applying this therapeutic system to aid immunotherapy in desmoplastic tumors. Using DiD-loaded liposome as a model nanoparticle, we showed that HDZ-liposome treatment significantly increased nanoparticle accumulation and penetration inside desmoplastic tumors. As a result, one single injection of doxorubicin-liposomes at a dose of 5 mg/kg resulted in strong tumor inhibition effect after HDZ-liposome pretreatment in the advanced desmoplastic melanoma with sizes over 400 mm
3 . Because HDZ is a widely used antihypertension drug, the findings here should be readily translatable for clinical benefits.- Published
- 2019
- Full Text
- View/download PDF
6. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers.
- Author
-
Shen L, Li J, Liu Q, Song W, Zhang X, Tiruthani K, Hu H, Das M, Goodwin TJ, Liu R, and Huang L
- Subjects
- Animals, Cell Proliferation, Chemokine CXCL12 genetics, Female, HEK293 Cells, Humans, Interleukin-10 genetics, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Nanoparticles chemistry, Triple Negative Breast Neoplasms immunology, Tumor Cells, Cultured, Tumor Microenvironment immunology, Chemokine CXCL12 immunology, Drug Delivery Systems, Interleukin-10 immunology, Killer Cells, Natural immunology, T-Lymphocytes, Cytotoxic immunology, Triple Negative Breast Neoplasms therapy
- Abstract
In many cancers, the tumor microenvironment (TME) is largely immune suppressive, blocking the antitumor immunity and resulting in immunotherapy resistance. Interleukin 10 (IL-10) is a major player controlling the immunosuppressive TME in different murine tumor models. Increased IL-10 production suppresses intratumoral dendritic cell production of interleukin 12, thereby limiting antitumor cytotoxic T-cell responses and activation of NK cells during therapy. We engineered, formulated, and delivered genes encoding an IL-10 protein trap to change immunosuppressive TME, which could enhance antitumor immunity. Additionally, to achieve stronger and long-term therapeutic efficacy in a pancreatic cancer model, we targeted C-X-C motif chemokine ligand 12 (CXCL12), a key factor for inhibiting T-cell tumor infiltration, and simultaneously delivered an IL-10 trap. Following three injections of the lipid-protamine-DNA (LPD) nanoparticles loaded with trap genes (IL-10 trap and CXCL12 trap), we found tumor growth reduction and significantly prolonged survival of the host compared to control groups. Furthermore, the combination trap gene treatment significantly reduced immunosuppressive cells, such as M2 macrophages, MDSCs, and PD-L1
+ cells, and activated immunosuppressive tolerogenic dendritic cells, NK cells, and macrophages intratumorally. We have also shown that, when effectively delivered to the tumor, the IL-10 trap gene alone can inhibit triple-negative breast cancer growth. This strategy may allow clinicians and researchers to change the immunosuppressive microenvironment in the tumor with either a single therapeutic agent or in combination with other immunotherapies to prime the immune system, preventing cancer invasion and prolonging patient survival.- Published
- 2018
- Full Text
- View/download PDF
7. Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.
- Author
-
Liu Q, Chen F, Hou L, Shen L, Zhang X, Wang D, and Huang L
- Subjects
- Animals, Antineoplastic Agents administration & dosage, Cell Death drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Disease Progression, Drug Carriers chemistry, Drug Delivery Systems, Drug Screening Assays, Antitumor, Immunosenescence drug effects, Melanoma pathology, Mice, Mice, Inbred C57BL, Mice, Knockout, Mitoxantrone administration & dosage, NIH 3T3 Cells, Pentacyclic Triterpenes, Skin Neoplasms pathology, Triterpenes administration & dosage, Tumor Microenvironment drug effects, Antineoplastic Agents therapeutic use, Immunotherapy, Melanoma therapy, Mitoxantrone therapeutic use, Nanoparticles chemistry, Skin Neoplasms therapy, Triterpenes therapeutic use
- Abstract
In desmoplastic melanoma, tumor cells and tumor-associated fibroblasts are the major dominators playing a critical role in the fibrosis morphology as well as the immunosuppressive tumor microenvironment (TME), compromising the efficacy of therapeutic options. To overcome this therapeutic hurdle, we developed an innovative chemo-immunostrategy based on targeted delivery of mitoxantrone (MIT) and celastrol (CEL), two potent medicines screened and selected with the best anticancer and antifibrosis potentials. Importantly, CEL worked in synergy with MIT to induce immunogenic tumor cell death. Here, we show that when effectively co-delivered to the tumor site at their optimal ratio by a TME-responsive nanocarrier, the 5:1 combination of MIT and CEL significantly triggered immunogenic tumor apoptosis and recovered tumor antigen recognition, thus eliciting overall antitumor immunity. Furthermore, the strong synergy benefitted the host in reduced drug exposure and side effects. Collectively, the nanocarrier-mediated chemo-immunotherapy successfully remodeled fibrotic and immunosuppressive TME, arrested cancer progression, and further inhibited tumor metastasis to major organs. The affected tumors remained dormant long after dosing stopped, resulting in a prolonged progression-free survival and sustained immune surveillance of the host bearing desmoplastic melanoma.
- Published
- 2018
- Full Text
- View/download PDF
8. Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.
- Author
-
Liu Q, Zhu H, Tiruthani K, Shen L, Chen F, Gao K, Zhang X, Hou L, Wang D, Liu R, and Huang L
- Subjects
- Animals, Antibiotics, Antineoplastic chemistry, Cell Line, Cell Proliferation drug effects, Cell Survival drug effects, Dose-Response Relationship, Drug, Doxorubicin chemistry, Drug Screening Assays, Antitumor, Female, Melanoma metabolism, Melanoma pathology, Mice, Mice, Inbred C57BL, Mutation, Proto-Oncogene Mas, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins B-raf metabolism, Structure-Activity Relationship, Wnt-5a Protein genetics, Wnt-5a Protein metabolism, Antibiotics, Antineoplastic pharmacology, Doxorubicin pharmacology, Melanoma drug therapy, Nanoparticles chemistry, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Tumor Microenvironment drug effects, Wnt-5a Protein antagonists & inhibitors
- Abstract
Development of an effective treatment against advanced tumors remains a major challenge for cancer immunotherapy. Approximately 50% of human melanoma is driven by B-Raf proto-oncogene mutation (BRAF mutant). Tumors with such mutation are desmoplastic, highly immunosuppressive, and often resistant to immune checkpoint therapies. We have shown that immunotherapy mediated by low-dose doxorubicin-induced immunogenic cell death was only partially effective for this type of tumor and not effective in long-term inhibition of tumor progression. Wnt family member 5A (Wnt5a), a signaling protein highly produced by BRAF mutant melanoma cells, has been implicated in inducing dendritic cell tolerance and tumor fibrosis, thus hindering effective antigen presentation and T-cell infiltration. We hypothesized that Wnt5a is a key molecule controlling the immunosuppressive tumor microenvironment in metastatic melanoma. Accordingly, we have designed and generated a trimeric trap protein, containing the extracellular domain of Fizzled 7 receptor that binds Wnt5a with a K
d ∼ 278 nM. Plasmid DNA encoding for the Wnt5a trap was delivered to the tumor by using cationic lipid-protamine-DNA nanoparticles. Expression of Wnt5a trap in the tumor, although transient, was greater than that of any other major organs including liver, resulting in a significant reduction of the Wnt5a level in the tumor microenvironment without systematic toxicity. Significantly, combination of Wnt5a trapping and low-dose doxorubicin showed great tumor growth inhibition and host survival prolongation. Our findings indicated that efficient local Wnt5a trapping significantly remodeled the immunosuppressive tumor microenvironment to facilitate immunogenic cell-death-mediated immunotherapy.- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.